CN107028888A - 一种主动靶向肿瘤emt细胞的新型抗耐药脂质体及其制备方法 - Google Patents
一种主动靶向肿瘤emt细胞的新型抗耐药脂质体及其制备方法 Download PDFInfo
- Publication number
- CN107028888A CN107028888A CN201710251088.8A CN201710251088A CN107028888A CN 107028888 A CN107028888 A CN 107028888A CN 201710251088 A CN201710251088 A CN 201710251088A CN 107028888 A CN107028888 A CN 107028888A
- Authority
- CN
- China
- Prior art keywords
- liposome
- tumour
- emt
- overriding resistance
- active targeting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 96
- 239000002502 liposome Substances 0.000 title claims abstract description 53
- 230000008685 targeting Effects 0.000 title claims abstract description 52
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 14
- 239000012528 membrane Substances 0.000 claims abstract description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 10
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 8
- 239000008363 phosphate buffer Substances 0.000 claims abstract description 8
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 5
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims abstract description 5
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 5
- 229940067606 lecithin Drugs 0.000 claims abstract description 5
- 235000010445 lecithin Nutrition 0.000 claims abstract description 5
- 239000000787 lecithin Substances 0.000 claims abstract description 5
- 229920005654 Sephadex Polymers 0.000 claims abstract description 4
- 239000012507 Sephadex™ Substances 0.000 claims abstract description 4
- 239000004698 Polyethylene Substances 0.000 claims abstract 2
- 230000004048 modification Effects 0.000 claims abstract 2
- 238000012986 modification Methods 0.000 claims abstract 2
- 229910052698 phosphorus Inorganic materials 0.000 claims abstract 2
- 239000011574 phosphorus Substances 0.000 claims abstract 2
- 229920000573 polyethylene Polymers 0.000 claims abstract 2
- 238000006243 chemical reaction Methods 0.000 claims description 11
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 9
- 235000002597 Solanum melongena Nutrition 0.000 claims description 6
- 244000061458 Solanum melongena Species 0.000 claims description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 239000008367 deionised water Substances 0.000 claims description 4
- 229910021641 deionized water Inorganic materials 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 238000003786 synthesis reaction Methods 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 230000033228 biological regulation Effects 0.000 claims description 3
- 230000009514 concussion Effects 0.000 claims description 3
- 238000000502 dialysis Methods 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 229910021529 ammonia Inorganic materials 0.000 claims description 2
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims 1
- FQVLRGLGWNWPSS-BXBUPLCLSA-N (4r,7s,10s,13s,16r)-16-acetamido-13-(1h-imidazol-5-ylmethyl)-10-methyl-6,9,12,15-tetraoxo-7-propan-2-yl-1,2-dithia-5,8,11,14-tetrazacycloheptadecane-4-carboxamide Chemical compound N1C(=O)[C@@H](NC(C)=O)CSSC[C@@H](C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@@H]1CC1=CN=CN1 FQVLRGLGWNWPSS-BXBUPLCLSA-N 0.000 abstract description 15
- 101000832889 Scheffersomyces stipitis (strain ATCC 58785 / CBS 6054 / NBRC 10063 / NRRL Y-11545) Alcohol dehydrogenase 2 Proteins 0.000 abstract description 14
- 238000005516 engineering process Methods 0.000 abstract description 2
- 230000035800 maturation Effects 0.000 abstract description 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 86
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 85
- 229930012538 Paclitaxel Natural products 0.000 description 50
- 229960001592 paclitaxel Drugs 0.000 description 50
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 50
- 102000000905 Cadherin Human genes 0.000 description 14
- 108050007957 Cadherin Proteins 0.000 description 14
- 229940125668 ADH-1 Drugs 0.000 description 13
- 101000796901 Gallus gallus Alcohol dehydrogenase 1 Proteins 0.000 description 13
- 210000004881 tumor cell Anatomy 0.000 description 11
- 108050000637 N-cadherin Proteins 0.000 description 10
- 206010059866 Drug resistance Diseases 0.000 description 8
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 238000011534 incubation Methods 0.000 description 5
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 4
- 108010087230 Sincalide Proteins 0.000 description 4
- 238000010609 cell counting kit-8 assay Methods 0.000 description 4
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 4
- PQMOXTJVIYEOQL-UHFFFAOYSA-N Cumarin Natural products CC(C)=CCC1=C(O)C(C(=O)C(C)CC)=C(O)C2=C1OC(=O)C=C2CCC PQMOXTJVIYEOQL-UHFFFAOYSA-N 0.000 description 3
- FSOGIJPGPZWNGO-UHFFFAOYSA-N Meomammein Natural products CCC(C)C(=O)C1=C(O)C(CC=C(C)C)=C(O)C2=C1OC(=O)C=C2CCC FSOGIJPGPZWNGO-UHFFFAOYSA-N 0.000 description 3
- 108010022476 N-Ac-CHAVC-NH2 Proteins 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 102000015728 Mucins Human genes 0.000 description 2
- 108010063954 Mucins Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000009194 climbing Effects 0.000 description 2
- 229960000956 coumarin Drugs 0.000 description 2
- 235000001671 coumarin Nutrition 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 101150021974 Adh1 gene Proteins 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- JVSCGVVWDLKMLX-UHFFFAOYSA-N N=NC=NN.N=NC=NN.N Chemical compound N=NC=NN.N=NC=NN.N JVSCGVVWDLKMLX-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000013127 Vimentin Human genes 0.000 description 1
- 108010065472 Vimentin Proteins 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000005048 vimentin Anatomy 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供一种主动靶向肿瘤EMT细胞的新型抗耐药脂质体及其制备方法，属于药物制剂领域。将二硬脂酰磷脂酰乙酰胺‐N‐羟基丁二酰亚胺‐聚乙二醇与环五肽ADH‑1为原料，制备环五肽‐聚乙二醇‐磷脂；将卵磷脂、胆固醇、甲氧基‐聚乙二醇‐磷脂、环五肽‐聚乙二醇‐磷脂按一定摩尔比溶于氯仿后，减压旋蒸至形成均匀透明的脂膜；加入预热磷酸盐缓冲液，涡旋、震荡、水化至脂膜完全脱落，将脂膜破碎后用葡聚糖凝胶柱进行纯化，得到新型抗耐药脂质体。本发明制备方法简单、技术成熟、具有广阔的应用前景，得到的新型抗耐药脂质体由环五肽‐聚乙二醇‐磷脂修饰，对肿瘤EMT细胞具有主动靶向性。
Description
技术领域
本发明属于药物制剂领域，提供了一种主动靶向肿瘤EMT细胞的新型抗耐药脂质体。
技术背景
现阶段，针对肿瘤细胞耐药，根据其耐药的发生机制，抑制通路中关键调控靶点，是改善和提高现有抗肿瘤药物敏感性的有效方法。肿瘤耐药包括原发性耐药和获得性耐药两大类。近年来的研究发现，上皮细胞间质转化(epithelial-mesenchymal transition,EMT)与肿瘤细胞耐药有密切的关系，一般发生EMT的肿瘤细胞可获得凋亡抵抗，而凋亡抵抗通常导致肿瘤放、化疗耐受。研究资料证明，EMT在多种肿瘤的化疗耐药中发挥重要作用，涉及的化疗药物包括紫杉醇、长春新碱等。因此，可通过靶向EMT来逆转肿瘤耐药，提高肿瘤细胞对药物的敏感性。
肿瘤细胞发生EMT时，细胞表面分子标志物的表达会发生变化：E-钙黏蛋白(E-cadherin)表达下降、N-钙黏蛋白(N-cadherin)表达增加、β-连环素(β-catenin)由细胞膜上向细胞质中分布等等。因此，阻断或反转肿瘤细胞发生EMT时产生的变化，能抑制肿瘤细胞EMT的发生，例如可通过针对肿瘤细胞发生EMT时特异表达的分子标志物，阻断其功能或者信号通路来实现这一目标。N-cadherin是肿瘤细胞发生EMT时细胞膜上显著高表达的分子标志物，是肿瘤细胞获得耐药性的关键分子，因此N-cadherin是一个很有潜力的治疗靶标来阻断EMT。环五肽ADH-1，能够选择性地结合并阻断N-cadherin，可作为N-cadherin的靶向分子用于肿瘤EMT细胞的靶向递送和治疗。
发明内容
针对现有技术存在的问题，本发明提供了一种主动靶向肿瘤EMT细胞的新型抗耐药脂质体，采用环五肽ADH-1作为主动靶向的靶头，利用受体与配体之间的相互作用，靶向作用于肿瘤EMT细胞表面的N-cadherin，进而阻断EMT过程，有效地逆转肿瘤的耐药性。采用脂质体作为载体，脂质体由中性磷脂制备，其理化性质与细胞接近，具有良好的生物相容性，同时载体的表面电荷为中性，降低了载体对细胞的毒性。
为了达到上述目的，本发明的技术方案为：
一种主动靶向肿瘤EMT细胞的新型抗耐药脂质体，采用环五肽-聚乙二醇-磷脂ADH-1-PEG2000-DSPE对脂质体进行修饰，该新型抗耐药脂质体对肿瘤EMT细胞具有主动靶向性，能够提高肿瘤细胞对化疗药物的敏感性，逆转肿瘤耐药。
上述主动靶向肿瘤EMT细胞的新型抗耐药脂质体的制备方法为：
第一步，合成靶向材料环五肽-聚乙二醇-磷脂ADH-1-PEG2000-DSPE
将二硬脂酰磷脂酰乙酰胺-N-羟基丁二酰亚胺-聚乙二醇NHS-PEG2000-DSPE和环五肽ADH-1按1.1～2:1的摩尔比溶于无水无氨的二甲基甲酰胺DMF后，置于茄型瓶中，加入适量三乙胺调节pH至8左右；室温、避光搅拌48h后，将反应液转移至截留分子量为3500的透析袋中，两端夹紧，用去离子水透析24h，以除去DMF及反应液中其他杂质；将透析袋中的溶液冷冻干燥后，得到产物ADH-1-PEG2000-DSPE，产物可用质谱进行鉴定。其中NHS-PEG2000-DSPE中聚乙二醇嵌段的分子量为2000。
第二步，合成主动靶向肿瘤EMT细胞的新型抗耐药脂质体
将卵磷脂、胆固醇、甲氧基-聚乙二醇-磷脂、ADH-1-PEG2000-DSPE室温下溶于氯仿后，置于茄型瓶中，37℃条件下减压旋蒸，除去有机溶剂，形成均匀透明的脂膜；再加入预热的磷酸盐缓冲液，涡旋震荡水化至脂膜完全脱落后，采用细胞破碎仪将脂膜破碎，破碎至溶液中出现蓝色乳光为止；最后将上述溶液用葡聚糖凝胶柱进行纯化，即得到该主动靶向肿瘤EMT细胞的新型抗耐药脂质体。所述的卵磷脂、胆固醇、甲氧基-聚乙二醇-磷脂、ADH-1-PEG2000-DSPE的摩尔比为65:20:4.35:0.5～1。
本发明的有益效果为：本发明方法制备方法简单、技术成熟、具有广阔的应用前景，也为相应给药系统的设计和发展打下基础。制备得到的主动靶向肿瘤EMT细胞的新型抗耐药脂质体能够显著增加对肿瘤EMT细胞的靶向性，提高肿瘤EMT细胞对药物的敏感性，有效逆转肿瘤耐药。制备载体采用中性磷脂，使其生物毒性明显降低。
附图说明
图1为ADH-1-PEG2000-DSPE的质谱结果图；
图2(a)为透射电镜观察到的主动靶向肿瘤EMT细胞的新型抗耐药脂质体的形态结果图；
图2(b)为采用动态光散射仪分析得到的主动靶向肿瘤EMT细胞的新型抗耐药脂质体的粒径分布图；
图3(a)为未经紫杉醇诱导的肿瘤MCF7细胞形态图；
图3(b)为紫杉醇诱导发生EMT的肿瘤MCF7细胞形态图；
图4(a)为采用激光共聚焦显微镜观察到的紫杉醇诱导发生EMT的MCF7细胞表面N-cadherin的表达情况；
图4(b)为采用激光共聚焦显微镜观察到未经紫杉醇诱导的肿瘤MCF7细胞表面N-cadherin的表达情况；
图5为免疫印迹分析未经紫杉醇诱导的肿瘤MCF7细胞和紫杉醇诱导发生EMT的肿瘤MCF7细胞相关蛋白的表达情况图；
图6为紫杉醇诱导发生EMT的肿瘤MCF7细胞对香豆素标记的未经ADH-1修饰的脂质体的摄取图，其中细胞核用DAPI进行染色。
图7为紫杉醇诱导发生EMT的肿瘤MCF7细胞对香豆素标记的主动靶向肿瘤EMT细胞的新型抗耐药脂质体的摄取图，其中细胞核用DAPI进行染色。
图8为提前用ADH-1孵育细胞后，紫杉醇诱导发生EMT的肿瘤MCF7细胞对香豆素标记的主动靶向肿瘤EMT细胞的新型抗耐药脂质体的摄取图，其中细胞核用DAPI进行染色。，
图9为用CCK-8法测定的包载紫杉醇的主动靶向肿瘤EMT细胞的新型抗耐药脂质体A-LP、包载紫杉醇的未经ADH-1修饰的脂质体LP和游离紫杉醇PTX对紫杉醇诱导发生EMT的肿瘤MCF7细胞的细胞毒作用。
具体实施方式
以下结合具体实施方式对本发明作进一步说明。
实施例1
第一步，合成靶向材料—环五肽-聚乙二醇-磷脂(ADH-1-PEG2000-DSPE)
精密称取5mg ADH-1肽和10mg NHS-PEG2000-DSPE，加入新鲜蒸馏的无水无氨二甲基甲酰胺(DMF)将其溶解。在室温，磁力搅拌下，将NHS-PEG2000-DSPE溶液逐滴加入到ADH-1溶液的茄型瓶中，同时加入适量三乙胺调节pH至8左右，室温、避光搅拌48h。反应结束后，将反应液转移至截留分子量为3500的透析袋中，两端夹紧，用去离子水透析24h，以除去DMF及反应液中其他杂质。随后将透析袋中的溶液冷冻干燥，即得到所需产物ADH-1-PEG2000-DSPE。
将所得样品，用基质辅助激光解吸电离飞行时间质谱(MALDI-TOF-MS)进行表征，图1为ADH-1-PEG2000-DSPE的MALDI-TOF-MS结果图：可以看到图中有两个峰，其中前峰是未反应完全的DSPE-PEG2000-NHS，为了使ADH-1充分反应它在反应中的加入是过量的。ADH-1的分子量是528，DSPE-PEG-NHS的分子量是2986，因此，材料的理论分子量为3514，质谱图后峰的分子量主要分布在3500，证明靶向材料的成功合成。
第二步，合成主动靶向肿瘤EMT细胞的新型抗耐药脂质体
将15.8mg卵磷脂、2.4mg胆固醇、4.0mg甲氧基-聚乙二醇-磷脂、0.6mgADH-1-PEG2000-DSPE溶解于氯仿后，37℃条件下减压旋蒸，除去有机溶剂，使其在茄型瓶底形成均匀透明的脂膜；然后加入预热的磷酸盐缓冲液涡旋、震荡、水化至脂膜完全脱落，用细胞破碎仪，破碎至出现蓝色乳光；最后将该溶液加到葡聚糖凝胶柱中，用pH为7.4的磷酸盐缓冲液洗脱，收集脂质体部分，即得到主动靶向肿瘤EMT细胞的新型抗耐药脂质体。
将主动靶向肿瘤EMT细胞的新型抗耐药脂质体滴加于透射电子显微镜(TEM)载样铜网上，待自然晾干后在TEM下观察，图2(a)中可见主动靶向肿瘤EMT细胞的新型抗耐药脂质体为类圆形纳米粒。
将主动靶向肿瘤EMT细胞的新型抗耐药脂质体用动态光散射仪进行粒径分析，图2(b)为其粒径分布，可以看出主动靶向肿瘤EMT细胞的新型抗耐药脂质体的粒径约为90nm，分布较为均一。
肿瘤EMT细胞模型的建立及表征
细胞模型的建立方法：先用初浓度为2nM的紫杉醇诱导MCF7细胞一周，再逐级增大紫杉醇浓度，进行诱导，至肿瘤MCF7细胞发生EMT(紫杉醇的终浓度为24nM，共诱导六个月)。图3(a)、(b)是用显微镜观察到的肿瘤MCF7发生EMT前后的形态图。
将未经紫杉醇诱导的肿瘤MCF-7细胞和紫杉醇诱导发生EMT的肿瘤MCF7细胞接种于放置盖破片的24孔板中，培养过夜，使细胞爬片。移除培养基，用预冷磷酸盐缓冲液(500μL/孔)洗两次，每次5min；室温条件下，用4％多聚甲醛(500μL/孔)固定15min，再用磷酸盐缓冲液洗三次；用5％牛血清白蛋白封闭1h；然后用N-cadherin的抗体孵育2h，同时设置阴性对照组(不加抗体，其他处理条件相同)，孵育后用磷酸盐缓冲液冲洗三次；再用FITC标记的二抗孵育1h，用磷酸盐缓冲液冲洗三次；再用5μg/mL的DAPI(400μL/孔)，避光条件下染核15min，最后用磷酸盐缓冲液冲洗三次；将盖玻片取出，置于载玻片上，用激光共聚焦显微镜进行观察。如图4所示，可以看出紫杉醇诱导发生EMT的肿瘤MCF7细胞表面的N-cadherin的表达量显著高于未经紫杉醇诱导的肿瘤MCF7的表达量，说明紫杉醇诱导发生EMT的肿瘤MCF7细胞确实发生了上皮间质转化，同时也表明本发明设计的主动靶向肿瘤EMT细胞的新型抗耐药脂质体通过N-cadherin这一靶标来实现靶向抑制肿瘤EMT细胞，提高对化疗药物敏感性的可行性。
接着，进行了免疫印迹分析，如图5所示，与未经紫杉醇诱导的肿瘤MCF7细胞相比，紫杉醇诱导发生EMT的肿瘤MCF7细胞的E-cadherin的表达量下降，vimentin的表达量增加，符合发生EMT的肿瘤细胞的变化，进一步证明了肿瘤EMT细胞模型的成功建立。
紫杉醇诱导发生EMT的肿瘤MCF7细胞对主动靶向肿瘤EMT细胞的新型抗耐药脂质体的摄取
将紫杉醇诱导发生EMT的肿瘤MCF7细胞接种于放置盖破片的24孔板中，培养过夜，使细胞爬片。移除培养基，分别用包载香豆素的未经ADH-1修饰的脂质体和主动靶向肿瘤EMT细胞的新型抗耐药脂质体处理细胞2h，同时设置受体提前封闭对照组：先用游离的ADH-1处理细胞1h，然后再用包载香豆素的主动靶向肿瘤EMT细胞的新型抗耐药脂质体处理2h。用激光共聚焦显微镜观察各处理组脂质体在紫杉醇诱导发生EMT的肿瘤MCF7细胞内的摄取情况。从图6和图7显示的结果可以看出：本发明设计的主动靶向肿瘤EMT细胞的新型抗耐药脂质体在紫杉醇诱导发生EMT的肿瘤MCF7细胞内的摄取量明显高于未经ADH-1修饰的脂质体的摄取量，说明该主动靶向肿瘤EMT细胞的新型抗耐药脂质体能主动靶向紫杉醇诱导发生EMT的肿瘤MCF7细胞。同时，从图8也可以看出提前用游离ADH-1处理的对照组，紫杉醇诱导发生EMT的肿瘤MCF7细胞对主动靶向肿瘤EMT细胞的新型抗耐药脂质体的摄取量与实验组相比有所下降，说明该主动靶向肿瘤EMT细胞的新型抗耐药脂质体是通过与紫杉醇诱导发生EMT的肿瘤MCF7细胞表面的N-cadherin的特异性结合，主动靶向进入细胞的。图6，图7，图8的比例尺为50.0μm。
主动靶向肿瘤EMT细胞的新型抗耐药脂质体的细胞毒性测定
首先，用CCK-8法测定了游离紫杉醇对未经紫杉醇诱导的肿瘤MCF7细胞和紫杉醇诱导发生EMT的肿瘤MCF7细胞的半抑制浓度(IC50)，结果分别为77.7nM和320.7nM，进一步证明上皮间质转化与肿瘤耐药确实有密切的联系，而且可以初步得出这样的结论：肿瘤细胞发生上皮间质转化后，会产生耐药，降低对化疗药物的敏感性。也再次证明，我们发明的主动靶向肿瘤EMT细胞的新型抗耐药脂质体通过靶向肿瘤EMT细胞来抗耐药的可行性。
接着，用CCK-8法测定了主动靶向肿瘤EMT细胞的新型抗耐药脂质体的细胞毒性：将紫杉醇诱导发生EMT的肿瘤MCF7细胞(5×103/孔)接种于96孔板中，培养过夜。分别加入100μL/孔的一系列紫杉醇浓度梯度的游离紫杉醇，包载紫杉醇的未经ADH-1修饰的脂质体和主动靶向肿瘤EMT细胞的新型抗耐药脂质体，同时以加入100μL/孔的完全培养基作为空白对照组，将细胞在细胞培养箱内培养48h，然后加入10μL/孔的CCK-8溶液继续培养1h，最后在酶标仪上，于450nm测定OD值。按以下公式计算细胞生存率：
细胞生存率(％)＝(OD样品/OD空白)×100％
从图9显示的结果表明：紫杉醇诱导发生EMT的肿瘤MCF7细胞确实对紫杉醇产生了耐药，即使当游离紫杉醇的浓度达到96nM时，对肿瘤EMT细胞的生存影响也很小(生存率为90％)；而用包载紫杉醇的主动靶向肿瘤EMT的新型抗耐药脂质体处理紫杉醇诱导产生EMT的肿瘤MCF7细胞，在紫杉醇的浓度为16nM时就与游离紫杉醇的生存率产生了显著性的差异，而且当紫杉醇的浓度为96nM时其生存率仅为50％，经计算，包载紫杉醇的主动靶向肿瘤EMT的新型抗耐药脂质体处理的细胞半抑制浓度为96nM，这与游离紫杉醇对紫杉醇诱导发生EMT的肿瘤MCF7细胞的半抑制浓度320.7nM相比有大幅度的下降，这说明：本发明的主动靶向肿瘤EMT的新型抗耐药脂质体显著提高了肿瘤EMT细胞对紫杉醇的敏感性，起到了逆转肿瘤耐药的效果。
实施例2
将第一步的ADH-1肽和NHS-PEG2000-DSPE的质量5mg和10mg改为5mg和5.5mg；将第二步的ADH-1-PEG2000-DSPE的质量0.6mg改为0.9mg；其它制备条件不变，制备主动靶向肿瘤EMT细胞的新型抗耐药脂质体。
实施例3
将第一步的ADH-1肽和NHS-PEG2000-DSPE的质量5mg和10mg改为5mg和7.5mg，将第二步的ADH-1-PEG2000-DSPE的质量0.6mg改为1.1mg，其它制备条件不变，制备主动靶向肿瘤EMT细胞的新型抗耐药脂质体。
Claims (6)
1.一种主动靶向肿瘤EMT细胞的新型抗耐药脂质体，其特征在于，该新型抗耐药脂质体由环五肽-聚乙二醇-磷脂修饰，新型抗耐药脂质体对肿瘤EMT细胞具有主动靶向性，能够提高肿瘤EMT细胞对药物的敏感性。
2.权利要求1所述的主动靶向肿瘤EMT细胞的新型抗耐药脂质体的制备方法，其特征在于以下步骤：
第一步，合成靶向材料环五肽-聚乙二醇-磷脂ADH-1-PEG2000-DSPE
将二硬脂酰磷脂酰乙酰胺-N-羟基丁二酰亚胺-聚乙二醇和环五肽按1.1～2:1的摩尔比溶于无水无氨的二甲基甲酰胺DMF后，置于茄型瓶中，加入三乙胺调节pH至8左右；室温、避光搅拌后，将反应液转移透析袋中，采用去离子水透析，除去DMF及反应液中其他杂质；将透析袋中的溶液冷冻干燥后，所得产物为环五肽-聚乙二醇-磷脂；
第二步，合成主动靶向肿瘤EMT细胞的新型抗耐药脂质体
室温下，将卵磷脂、胆固醇、甲氧基-聚乙二醇-磷脂、环五肽-聚乙二醇-磷脂按65:20:4.35:0.5～1的摩尔比溶于氯仿后，置于茄型瓶中，37℃条件下减压旋蒸，除去有机溶剂，形成均匀透明的脂膜；再加入预热的磷酸盐缓冲液，涡旋震荡水化至脂膜完全脱落后，采用细胞破碎仪将脂膜破碎，破碎至溶液中出现蓝色乳光为止；最后将上述溶液用葡聚糖凝胶柱进行纯化，得到主动靶向肿瘤EMT细胞的新型抗耐药脂质体。
3.根据权利要求2所述的新型抗耐药脂质体的制备方法，其特征在于，第一步中所述的室温、避光搅拌时间为48小时。
4.根据权利要求2或3所述的新型抗耐药脂质体的制备方法，其特征在于，第一步中所述透析袋的截留分子量为3500，去离子水透析时间为24小时。
5.根据权利要求2或3所述的新型抗耐药脂质体的制备方法，其特征在于，第一步中所述的二硬脂酰磷脂酰乙酰胺-N-羟基丁二酰亚胺-聚乙二醇中聚乙二醇嵌段分子量为2000。
6.根据权利要求4所述的新型抗耐药脂质体的制备方法，其特征在于，第一步中所述的二硬脂酰磷脂酰乙酰胺-N-羟基丁二酰亚胺-聚乙二醇中聚乙二醇嵌段分子量为2000。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710251088.8A CN107028888B (zh) | 2017-04-18 | 2017-04-18 | 一种主动靶向肿瘤emt细胞的抗耐药脂质体及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710251088.8A CN107028888B (zh) | 2017-04-18 | 2017-04-18 | 一种主动靶向肿瘤emt细胞的抗耐药脂质体及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107028888A true CN107028888A (zh) | 2017-08-11 |
| CN107028888B CN107028888B (zh) | 2020-12-11 |
Family
ID=59536488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710251088.8A Expired - Fee Related CN107028888B (zh) | 2017-04-18 | 2017-04-18 | 一种主动靶向肿瘤emt细胞的抗耐药脂质体及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107028888B (zh) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101113159A (zh) * | 2006-11-03 | 2008-01-30 | 江其生 | 预防与治疗肺癌细胞侵袭转移的反义寡核苷酸的结构及用途 |
| WO2008039525A2 (en) * | 2006-09-27 | 2008-04-03 | Adherex Technologies, Inc. | Cadherin antagonists in combination with anticancer agents for use in cancer treatment |
| CN101327190A (zh) * | 2008-07-29 | 2008-12-24 | 北京大学 | 一种供注射用的抗肿瘤长循环靶向脂质体 |
| CN102764234A (zh) * | 2012-08-03 | 2012-11-07 | 上海现代药物制剂工程研究中心有限公司 | 一种盐酸拓扑替康靶向脂质体制剂及其制备方法 |
-
2017
- 2017-04-18 CN CN201710251088.8A patent/CN107028888B/zh not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008039525A2 (en) * | 2006-09-27 | 2008-04-03 | Adherex Technologies, Inc. | Cadherin antagonists in combination with anticancer agents for use in cancer treatment |
| CN101113159A (zh) * | 2006-11-03 | 2008-01-30 | 江其生 | 预防与治疗肺癌细胞侵袭转移的反义寡核苷酸的结构及用途 |
| CN101327190A (zh) * | 2008-07-29 | 2008-12-24 | 北京大学 | 一种供注射用的抗肿瘤长循环靶向脂质体 |
| CN102764234A (zh) * | 2012-08-03 | 2012-11-07 | 上海现代药物制剂工程研究中心有限公司 | 一种盐酸拓扑替康靶向脂质体制剂及其制备方法 |
Non-Patent Citations (2)
| Title |
|---|
| YASUSHI SHINTANI ETAL: "ADH-1 suppresses N-cadherin-dependent pancreatic cancer progression", 《INTERNATIONAL JOURNAL OF CANCER》 * |
| 胡戴: "K237修饰的紫杉醇长循环靶向脂质体的制备及体外评价", 《湖北中医药大学硕士学位论文》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107028888B (zh) | 2020-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Qin et al. | In vitro and in vivo investigation of glucose-mediated brain-targeting liposomes | |
| Cerritelli et al. | PEG-SS-PPS: reduction-sensitive disulfide block copolymer vesicles for intracellular drug delivery | |
| WO2018010202A1 (zh) | 一种抗肿瘤药物三元偶联物及合成和应用 | |
| Fu et al. | Liposomes actively recognizing the glucose transporter GLUT1 and integrin αvβ3 for dual‐targeting of glioma | |
| Bai et al. | Liposomes encapsulated iridium (III) polypyridyl complexes enhance anticancer activity in vitro and in vivo | |
| CN107936058B (zh) | 多西紫杉醇衍生物及其制备方法和应用 | |
| CN106432203B (zh) | 基于四苯乙烯基的Gemini型两亲性化合物及其制备方法和用途 | |
| CN110433292B (zh) | 一种双靶向材料及其在药物传递中的应用 | |
| CN109316465A (zh) | 一种无机纳米可生物降解多靶点靶向智能给药系统、其制备方法及应用 | |
| JP2019507190A (ja) | 卵巣癌用の特異的に標的化された生分解性両親媒性ポリマー、それから製造されたポリマーベシクル及びその使用 | |
| Zhou et al. | Selenium-doped hydroxyapatite biopapers with an anti-bone tumor effect by inducing apoptosis | |
| Wang et al. | Intracellular GSH-activated galactoside photosensitizers for targeted photodynamic therapy and chemotherapy | |
| Misra et al. | Gene transfection in high serum levels: case studies with new cholesterol based cationic gemini lipids | |
| CN108619527B (zh) | 一种抗肿瘤耐药的介孔二氧化钛纳米药物组合物及其制备方法 | |
| CN107049991B (zh) | 一种新型双重靶向抑制肿瘤细胞迁移与侵袭的介孔二氧化硅纳米给药系统及其制备方法 | |
| Zeng et al. | Synthesis, Characterization, and Evaluation of a Novel Amphiphilic Polymer RGD‐PEG‐Chol for Target Drug Delivery System | |
| CN107550864A (zh) | Eppt多肽‑聚乙二醇‑磷脂复合膜材料、其制备方法及主动靶向脂质体递药系统和应用 | |
| Gileva et al. | Lipoamino acid-based cerasomes for doxorubicin delivery: Preparation and in vitro evaluation | |
| CN111000823A (zh) | 一种同时载有siRNA和顺铂前药的新型酸敏纳米载体及其制备方法与应用 | |
| CN106633015B (zh) | 桥联的聚乙二醇-脂肪族聚酯嵌段共聚物、其制备方法、中间体和用途 | |
| Cheng et al. | pH-responsive and CD44-targeting polymer micelles based on CD44p-conjugated amphiphilic block copolymer PEG-b-HES-b-PLA for delivery of emodin to breast cancer cells | |
| Matsui et al. | Lung carcinoma with spindle cell components: sixteen cases examined by immunohistochemistry | |
| CN107028888A (zh) | 一种主动靶向肿瘤emt细胞的新型抗耐药脂质体及其制备方法 | |
| Wang et al. | A co-delivery system based on chlorin e6-loaded ROS-sensitive polymeric prodrug with self-amplified drug release to enhance the efficacy of combination therapy for breast tumor cells | |
| Zhang et al. | Nanomicelles for GLUT1-targeting hepatocellular carcinoma therapy based on NADPH depletion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20201211 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |